Proposed diagnostic and prognostic markers of primary malignant hepatic vascular neoplasms.
Angiosarcoma
Diagnosis
Epithelioid hemangioendothelioma
Liver
Malignancy
Vascular neoplasm
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
13 May 2024
13 May 2024
Historique:
received:
14
05
2023
accepted:
01
04
2024
medline:
14
5
2024
pubmed:
14
5
2024
entrez:
13
5
2024
Statut:
epublish
Résumé
Primary malignant hepatic vascular tumors with various malignant potentials include epithelioid hemangioendothelioma (EHE) and angiosarcoma (AS), which may overlap pathologically. This study aimed to compare the pathological findings of hepatic EHE with those of AS, in association with patient outcomes. Fifty-nine histologically confirmed patients with 34 EHE and 25 AS were admitted to a tertiary hospital from 2003 to 2020. Their EHE and AS pathological features were compared. Immunohistochemistry for CD31, ERG, CAMTA-1, TFE3, P53, and Ki-67 labeling was performed on paraffin-embedded blocks. Markers, along with histological findings, were analyzed for the purposes of diagnostic and prognostic significance by multivariate analysis. CAMTA-1 was 91.2% positive in EHE, but negative in AS (p = < 0.001). AS was significantly correlated to an aberrant p53 expression, high Ki-67 labeling, and high mitotic activity, compared to EHE (all, p = < 0.001). EHE can be classified as low grade (LG) and high grade (HG) using the prognostic values of mitotic activity and ki-67 labeling (sensitivity = 1, specificity = 1). Low grade-EHE showed significantly better overall survival than high grade-EHE (p = 0.020). Immunohistochemistry for CAMTA-1, P53, and Ki-67 labeling may help distinguish EHE and AS in histologically ambiguous cases, especially small biopsied tissue. Moreover, the combination of mitotic activity and Ki-67 labeling can be a prognostic factor for EHE with various clinical features.
Identifiants
pubmed: 38741104
doi: 10.1186/s13000-024-01482-5
pii: 10.1186/s13000-024-01482-5
doi:
Substances chimiques
Biomarkers, Tumor
0
Ki-67 Antigen
0
CAMTA1 protein, human
0
Calcium-Binding Proteins
0
Trans-Activators
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
68Subventions
Organisme : National Research Foundation of Korea
ID : 2020R1F1A1074056
Organisme : Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea
ID : 2022IP0032
Informations de copyright
© 2024. The Author(s).
Références
Kim HR, Rha SY, Cheon SH, Roh JK, Park YN, Yoo NC. Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma. Ann Oncol Apr. 2009;20(4):780–7. https://doi.org/10.1093/annonc/mdn702 .
doi: 10.1093/annonc/mdn702
Koch M, Nielsen GP, Yoon SS. Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas. J Surg Oncol Mar. 2008;15(4):321–9. https://doi.org/10.1002/jso.20973 .
doi: 10.1002/jso.20973
Ganeshan D, Pickhardt PJ, Morani AC, et al. Hepatic hemangioendothelioma: CT, MR, and FDG-PET-CT in 67 patients-a bi-institutional comprehensive cancer center review. Eur Radiol May. 2020;30(5):2435–42. https://doi.org/10.1007/s00330-019-06637-3 .
doi: 10.1007/s00330-019-06637-3
Choi HH, Manning MA, Mehrotra AK, Wagner S, Jha RC. Primary hepatic neoplasms of vascular origin: key imaging features and differential diagnoses with radiology-pathology correlation. AJR Am J Roentgenol Dec. 2017;209(6):W350–9. https://doi.org/10.2214/AJR.17.18100 .
doi: 10.2214/AJR.17.18100
Rosenberg A, Agulnik M. Epithelioid Hemangioendothelioma: update on diagnosis and treatment. Curr Treat Options Oncol Mar. 2018;15(4):19. https://doi.org/10.1007/s11864-018-0536-y .
doi: 10.1007/s11864-018-0536-y
Kounis I, Lewin M, Laurent-Bellue A, et al. Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation? Ther Adv Med Oncol. 2022;14:17588359221086909. https://doi.org/10.1177/17588359221086909 .
doi: 10.1177/17588359221086909
pubmed: 35340695
pmcid: 8949775
Liu Z, Yi L, Chen J, et al. Comparison of the clinical and MRI features of patients with hepatic hemangioma, epithelioid hemangioendothelioma, or angiosarcoma. BMC Med Imaging Jun. 2020;29(1):71. https://doi.org/10.1186/s12880-020-00465-4 .
doi: 10.1186/s12880-020-00465-4
Zhou Y, Hou P, Wang F, Li B, Gao J. Primary hepatic malignant vascular tumors: a follow-up study of imaging characteristics and clinicopathological features. Cancer Imaging Aug. 2020;14(1):59. https://doi.org/10.1186/s40644-020-00336-9 .
doi: 10.1186/s40644-020-00336-9
Seo JW, Kim SH, Kim AY, Jeong WK, Woo JY, Park WJ. Differentiating primary hepatic angiosarcomas from hemangiomatosis and epithelioid hemangioendotheliomas using gadoxetic acid-enhanced and diffusion-weighted MR imaging. Jpn J Radiol Nov. 2017;35(11):655–63. https://doi.org/10.1007/s11604-017-0676-1 .
doi: 10.1007/s11604-017-0676-1
Jung H, Kim HN, Jang Y, Park CK, Ha SY. CAMTA-1 Expression in 24 Cases of Hepatic Epithelioid Hemangioendothelioma in a Single Institute: Diagnostic Utility for Differential Diagnosis from Hepatic Angiosarcoma. In Vivo. Nov-Dec. 2019;33(6):2293–2297. https://doi.org/10.21873/invivo.11736 .
Shibuya R, Matsuyama A, Shiba E, Harada H, Yabuki K, Hisaoka M. CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma. Histopathology Dec. 2015;67(6):827–35. https://doi.org/10.1111/his.12713 .
doi: 10.1111/his.12713
Bankhead P, Loughrey MB, Fernández JA, et al. QuPath: open source software for digital pathology image analysis. Sci Rep Dec. 2017;4(1):16878. https://doi.org/10.1038/s41598-017-17204-5 .
doi: 10.1038/s41598-017-17204-5
Alves VAF, Rimola J. Malignant vascular tumors of the liver in adults. Semin Liver Dis Feb. 2019;39(1):1–12. https://doi.org/10.1055/s-0038-1676120 .
doi: 10.1055/s-0038-1676120
Antonescu C. Malignant vascular tumors—an update. Mod Pathol Jan. 2014;27(Suppl 1):S30–8. https://doi.org/10.1038/modpathol.2013.176 .
doi: 10.1038/modpathol.2013.176
Doyle LA, Fletcher CD, Hornick JL. Nuclear expression of CAMTA1 distinguishes Epithelioid Hemangioendothelioma from histologic mimics. Am J Surg Pathol Jan. 2016;40(1):94–102. https://doi.org/10.1097/pas.0000000000000511 .
doi: 10.1097/pas.0000000000000511
Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer Aug. 2011;50(8):644–53. https://doi.org/10.1002/gcc.20886 .
doi: 10.1002/gcc.20886
Tanas MR, Sboner A, Oliveira AM, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med Aug. 2011;31(98):98ra82. https://doi.org/10.1126/scitranslmed.3002409 .
doi: 10.1126/scitranslmed.3002409
Anderson T, Zhang L, Hameed M, Rusch V, Travis WD, Antonescu CR. Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions. Am J Surg Pathol Jan. 2015;39(1):132–9. https://doi.org/10.1097/PAS.0000000000000346 .
doi: 10.1097/PAS.0000000000000346
Patel NR, Salim AA, Sayeed H, et al. Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1-CAMTA1 fusion variants. Histopathology Nov. 2015;67(5):699–708. https://doi.org/10.1111/his.12697 .
doi: 10.1111/his.12697
Antonescu CR, Le Loarer F, Mosquera JM, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer Aug. 2013;52(8):775–84. https://doi.org/10.1002/gcc.22073 .
doi: 10.1002/gcc.22073
Dermawan JK, Azzato EM, Billings SD, et al. YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases. Mod Pathol Dec. 2021;34(12):2211–21. https://doi.org/10.1038/s41379-021-00879-7 .
doi: 10.1038/s41379-021-00879-7
Flucke U, Vogels RJ, de Saint Aubain Somerhausen N, et al. Epithelioid Hemangioendothelioma: clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 cases. Diagn Pathol Jul. 2014;1(1):131. https://doi.org/10.1186/1746-1596-9-131 .
doi: 10.1186/1746-1596-9-131
Ishak KG, Sesterhenn IA, Goodman ZD, Rabin L, Stromeyer FW. Epithelioid hemangioendothelioma of the liver: a clinicopathologic and follow-up study of 32 cases. Hum Pathol Sep. 1984;15(9):839–52. https://doi.org/10.1016/s0046-8177(84)80145-8 .
doi: 10.1016/s0046-8177(84)80145-8
Mehrabi A, Kashfi A, Fonouni H, et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer Nov. 2006;1(9):2108–21. https://doi.org/10.1002/cncr.22225 .
doi: 10.1002/cncr.22225
Rosenbaum E, Jadeja B, Xu B, et al. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Mod Pathol Apr. 2020;33(4):591–602. https://doi.org/10.1038/s41379-019-0368-8 .
doi: 10.1038/s41379-019-0368-8
Gigante E, Paradis V, Ronot M, et al. New insights into the pathophysiology and clinical care of rare primary liver cancers. JHEP Rep Feb. 2021;3(1):100174. https://doi.org/10.1016/j.jhepr.2020.100174 .
doi: 10.1016/j.jhepr.2020.100174